Byron Breeding, PA
Medical · Jackson, TNNPI 1548241359
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 589 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 589 payments — averaging $14.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Pfizer$767
- Lilly USA, LLC$645
- Amgen$415
- Boehringer Ingelheim$380
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,568100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 153 | $1,927 |
| Novo Nordisk | 90 | $1,339 |
| Pfizer | 52 | $767 |
| Lilly USA, LLC | 49 | $645 |
| Amgen | 30 | $415 |
| Boehringer Ingelheim | 20 | $380 |
| Lundbeck LLC | 19 | $357 |
| Otsuka America Pharmaceutical, Inc. | 18 | $287 |
| Biohaven Pharmaceuticals, Inc. | 21 | $264 |
| Johnson & Johnson | 18 | $260 |
| Bayer | 16 | $252 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $205 |
| Novartis | 17 | $191 |
| Amarin Pharma, Inc. | 12 | $187 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $171 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $135 |
| Phathom Pharmaceuticals, Inc. | 7 | $103 |
| Acadia Pharmaceuticals Inc | 4 | $102 |
| Axsome Therapeutics, Inc. | 4 | $92 |
| AstraZeneca | 4 | $75 |
| Sanofi-aventis U.S. LLC | 5 | $68 |
| GSK | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Antares Pharma, Inc. | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Mylan Specialty L.p. | 2 | $33 |
| Medtronic | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Radius Health, Inc. | 1 | $20 |
| Merck | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
How this compares
$8,568 in reported general payments places this provider in the 95th percentile of 480 medical providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $60,786 |
| FarxigaDapagliflozin Propanediol | 80 | $59,080 |
| EliquisApixaban | 70 | $58,109 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $55,668 |
| MounjaroTirzepatide | 43 | $54,537 |
| JardianceEmpagliflozin | 53 | $48,878 |
| JanumetSitagliptin Phos/Metformin Hcl | 51 | $46,788 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $31,249 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $26,645 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 31 | $24,628 |
| XareltoRivaroxaban | 39 | $23,526 |
| RexultiBrexpiprazole | 17 | $23,393 |
| JanuviaSitagliptin Phosphate | 30 | $22,785 |
| LinzessLinaclotide | 27 | $22,773 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $21,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Janumet Xr, Januvia | $14 | $94,200112 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $75 | $84,348119 claims |
| Novo NordiskOzempic, Rybelsus | $1,339 | $77,09175 claims |
| GSKTrelegy Ellipta, Shingrix | $47 | $60,31688 claims |
| PfizerEliquis | $767 | $58,10970 claims |
| Lilly USA, LLCMounjaro | $645 | $54,53743 claims |
| Boehringer IngelheimJardiance | $380 | $48,87853 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $68 | $26,64529 claims |
| Johnson & JohnsonXarelto | $260 | $23,52639 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $287 | $23,39317 claims |
| AbbVieLinzess | $1,927 | $22,77327 claims |
| NovartisEntresto | $191 | $17,51027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 480 medical providers in Tennessee.
Other medical in Jackson
- Maria WoodChattanooga$130K
- Alyssa JamesonFranklin$65K
- Melissa LambertHendersonville$47K
- Stephanie HowardKnoxville$18K
- Evan HatfillNashville$18K
- Meredith McDanielChattanooga$17K
- Janet BreedingKnoxville$15K
- Paul MabenKnoxville$13K
- Hannah KirkGreeneville$13K
- Scarlett FordNashville$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.